Brief: Ascletis Pharma Says China's NMPA Approved IND Application Of Asc10 For Monkeypox Indication
26/01/2023 14:18
Jan 26 (Reuters) - Ascletis Pharma Inc 1672.HK :
* CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED
INVESTIGATIONAL NEW DRUG APPLICATION OF ASC10 FOR MONKEYPOX
INDICATION
Source text for Eikon: ID:nHKSbnN4Fx
Further company coverage: 1672.HK
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026